Doximity (DOCS) Form 144: 20,000 shares via Morgan Stanley; recent insider sales reported
Rhea-AI Filing Summary
Doximity, Inc. (DOCS) Form 144 notifies the market that a person plans to sell 20,000 shares of Common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,275,566.00 and reports 187,299,459 shares outstanding. The shares to be sold were acquired the same day, 08/15/2025, by stock option exercise from the issuer and paid for in cash. The filer also reported two recent sales in the past three months: 10,000 shares sold on 06/25/2025 for $600,000.00 and 10,000 shares sold on 05/23/2025 for $505,796.00. The signer certifies no undisclosed material adverse information.
Positive
- Transparent disclosure of planned sale, acquisition method, broker, and dollar amounts consistent with Rule 144 requirements
- Recent sales fully reported, showing prior transactions and gross proceeds for market clarity
Negative
- Insider liquidity events (option exercise and planned sale) indicate shares were sold by an insider in the past three months
- No trading plan date is provided on the form to indicate whether sales are pursuant to a Rule 10b5-1 plan
Insights
TL;DR: Routine insider sale disclosure showing option exercise and planned sale of 20,000 shares; materiality appears limited.
The Form 144 documents a planned sale executed through a broker with clear acquisition details: the shares were acquired via stock option exercise from the issuer on the same date as the planned sale and paid in cash. Two prior sales by the same person in the past three months are recorded, totaling 20,000 shares and gross proceeds of $1,105,796.00. As a compliance filing, it provides transparent information for market participants but does not include operational or financial performance details.
TL;DR: Proper Rule 144 disclosure completed; shows insider liquidity events but no governance or control changes disclosed.
The notice complies with Rule 144 format by identifying the broker, share class, acquisition method, and recent sales. The acquisition method (stock option exercise from the issuer) and immediate planned sale are explicitly stated, and the signer affirms absence of undisclosed material adverse information. There is no indication of a change in control, related-party transaction beyond ordinary option exercise, or a trading plan date provided on this form.
FAQ
What quantity of DOCS shares is the filer proposing to sell on 08/15/2025?
How were the 20,000 DOCS shares acquired?
What are the recent insider sales reported in the past three months for DOCS?
What is the aggregate market value and shares outstanding noted in the filing?
Does the Form 144 state whether the filer knows of any undisclosed material adverse information?